Experimental composite guidance conduits for peripheral nerve repair: An evaluation of ion release

Poly (lactide-co-glycolide) (PLGA) — Pluronic F127 — glass composites have demonstrated excellent potential, from the perspective of controlled mechanical properties and cytocompatibility, for peripheral nerve regeneration. In addition to controlling the mechanical properties and cytotoxicity for such composite devices, the glass component may mediate specific responses upon implantation via degradation in the physiological environment and release of constituent elements. However, research focused on quantifying the release levels of such therapeutic ions from these experimental medical devices has been limited. To redress the balance, this paper explores the ion release profiles for Si4+, Ca2+, Na+, Zn2+, and Ce4+ from experimental composite nerve guidance conduits (CNGC) comprising PLGA (at 12.5, and 20 wt.%), F127 (at 0, 2.5 and 5 wt.%) and various loadings of Si–Ca–Na–Zn–Ce glass (at 20 and 40 wt.%) for incubation periods of up to 28 days. The concentration of each ion, at various time points, was determined using Inductively Coupled Plasma–Atomic Emission Spectrometry (Perkin Elmer Optima 3000). It was observed that the Si4+, Na+, Ca2+, Zn2+ release from CNGCs in this study ranged from 0.22 to 6.477 ppm, 2.307 to 3.277 ppm, 40 to 119 ppm, and 45 to 51 ppm, respectively. The Ce4+ concentrations were under the minimum detection limits for the ICP instrument utilized. The results indicate that the ion release levels may be appropriate to mediate therapeutic effects with respect to peripheral nerve regeneration. The data generated in this paper provides requisite evidence to optimize composition for pre-clinical evaluation of the experimental composite.

Highlights
► Time-dependent degradation studies of PLGA/glass composite nerve guidance conduits (NGCs).
► Si4+, Na+, Ca2+ and Zn2+ release levels for the glass containing NGCs are presented.
► Release levels may mediate therapeutic effects to provoke nerve regeneration.
► Data provides requisite evidence to optimize composition to pre-clinical requirements.